ERINA was described as an estrogen-responsive oncogenic factor because its knock-down inhibits cell-cycle progression and cancer cell proliferation both in vitro and in xenograft in vivo models, while its over-expression promotes cell growth and cell-cycle progression [101]. The gene discussed is LINC00992; the disease is cancer.